Bullish Case: Return-surface likelihood concentrates around small-magnitude outcomes (roughly -10% to +10%) for near multi-year holds, matching WALD’s mean-reverting tape. Helium’s AI baseline is neutral (0%) with negative forecast–realized correlation (-0.4), suggesting recent weakness can overshoot and revert absent new negatives. Earlier asset-monetization/regulatory-win expectations were not evidenced by May 2026; a delayed Obagi/IP monetization or partnership could still trigger a retail-amplified rerate. SPY implied vol elevated into 3–6 months supports upside spikes.

Bearish Case: WALD return surface shows a thick likelihood mass at negative multi-year returns (roughly -20% to -60%), and price is still deeply off prior levels (-82% vs 5y). Prior bearish cash-burn/dilution warnings look directionally consistent with the single-name drift since March–May 2026, while the expected monetization/regulatory catalysts have yet to be evidenced. Neutral AI forecast with negative correlation also fits “fade” rallies; with SPY vol supporting risk-off tails, dilution/liquidity stress remains a core uncertainty.

Potential Outcomes:

1. 20% Asset sale/rerate: 8‑K/press within 90d; close >$2.30 in 30d.
2. 10% FDA/partner: filing within 120d; move >$2.43 within 45d.
3. 38% Dilution/cash burn: ATM/10‑Q/S‑3 in next 2 quarters; drift to $1.1–$1.3.
4. 22% Mean‑reversion pop: holds ~$1.6–$1.9; brief break above $2.00 then fade in 30–45d.
5. 10% Liquidity/delist: NASDAQ min‑bid warning/reverse split; sub‑$1.0 print.

July 22, 2026